162809-97-4

Upstream product

• 18162-48-6 tert-butyldimethylsilyl chloride 
• 78432-77-6 10-deacetylpaclitaxel 
• 114655-02-6 2'-O-(tert-butyldimethylsilyl)paclitaxel 
• 33069-62-4 taxol 
• 994-30-9 triethylsilyl chloride 
• 162375-26-0 2'-O-(tert-butyldimethylsilyl)-10-deacetylpaclitaxel 

Downstream Products

• 849213-05-4 2-O-TES-7-O-methylthiomethyl-9-α-OH-10-epi-paclitaxel 
• 849213-04-3 2'-O-TES-9-α-OH-10-epi-paclitaxel 
• 849213-07-6 C₅₄H₆₇NO₁₄Si 
• 849213-06-5 7-O-methylthiomethyl-9-α-OH-10-epi-paclitaxel 
• 849213-08-7 C₄₈H₅₃NO₁₄ 
• 1052091-65-2 C₆₂H₇₁NO₁₇ 
• 1051405-75-4 C₅₅H₅₉NO₁₅ 
• 1051405-72-1 C₄₇H₅₃NO₁₄ 
• 1051405-78-7 C₃₉H₄₆O₁₂ 
• 1093959-14-8 C₆₂H₈₃NO₁₆Si₂ 
• 162664-55-3 2'-TBS-10-deacetyl-7-TES-10α-hydroxypaclitaxel 

Relevant academic research and scientific papers

Syntheses of Novel C-9 and C-10 Modified Bioactive Taxanes

A method has been developed for the syntheses of hitherto unreported C-9 and C-10 modified taxanes.These analogs demonstrated excellent to good cytotoxicity against B 16 melanoma cells.

Chemical modification of paclitaxel (taxol) reduces P-glycoprotein interactions and increases permeation across the blood-brain barrier in vitro and in situ

The purpose of this work was to introduce a chemical modification into the paclitaxel (Taxol) structure to reduce interactions with the product of the multidrug resistant type 1 (MDR1) gene, P-glycoprotein (Pgp), resulting in improved blood-brain barrier

TAXANE ANALOGS FOR THE TREATMENT OF BRAIN CANCER

Provided herein are compounds and methods for the treatment of brain cancer in a mammal, wherein the method comprises the administration to the mammal a compound that stabilizes tubulin dimers or microtubles at G2-M interface during mitosis but is not a s

Biologically Active Taxane Analogs and Methods of Treatment

The present application relates to new taxane analogs, pharmaceutical compositions comprising such analogs and methods of treating cancer comprising such compositions. The compounds according to the present application have the general formula: wherein R

BIOLOGICALLY ACTIVE TAXANE ANALOGS AND METHODS OF TREATMENT BY ORAL ADMINISTRATION

The present invention relates to a novel chemical compound of formula S-(I) for use in the treatment of cancer, to compositions containing said compound, methods of manufacture and combinations with other therapeutic agents.

Synthesis of 7- and 10-spermine conjugates of paclitaxel and 10-deacetyl-paclitaxel as potential prodrugs

Efficient syntheses of two taxol analogs bearing the linear polyamine spermine at 7- and 10-positions of paclitaxel and 10-deacetyl-paclitaxel have been developed. These polyamine-taxol-conjugates were isolated as water soluble difluoride salts. The aim o

9,10-alpha,alpha-OH-TAXANE ANALOGS AND METHODS FOR PRODUCTION THEREOF

The present invention relates to new taxane analogs useful for the treatment of cancer as well as methods for producing the same. The chemical compounds according to the present invention have the general Formula (I) wherein R1 and R2 are each selected fr

Design, Synthesis, and Bioactivities of Steroid-Linked Taxol Analogues as Potential Targeted Drugs for Prostate and Breast Cancer

The female steroid hormone 3,17β-estradiol (2) was selected as an agent to target taxol (1) to estrogen receptor (ER) positive breast cancer cells. Estradiol-taxol conjugates (ETC) were synthesized through linkages from the 11- or 16-position of estradiol

The chemistry of the taxane diterpene: Stereoselective reductions of taxanes

Stereoselective reductions of taxanes are detailed. Chelation- controlled reductions employing SmI2 are described for the stereoselective reduction of the 9-keto functionality of the diterpene moiety of several taxanes. In all cases the 9β-hydr